Intertek Expands Non-Destructive Testing Capabilities with Acquisition of European Market Leader, NDT Services Limited
10.9.2012 21:07:01 CEST | Business Wire | Press release
Intertek Group plc (Intertek), the leading international provider of quality services to a wide range of industries, announces that it has acquired NDT Services Limited (NSL), a provider of non-destructive testing (NDT) services to the aerospace, power and petrochemical sectors.
NSL offers on-site and laboratory based NDT of industrial components used in a wide range of applications such as aircraft, pipelines, power stations, refineries and oil platforms. NDT can help assure safety and reliability by identifying any flaws or defects in products or components without disrupting operations or delaying processes. As a quality assurance management tool, NDT can help avoid potential loss of productivity through unplanned plant shutdowns which may occur if materials, products or equipment fail to achieve their design requirements or projected life span. In addition NSL also operates a technical staffing service, offering supplemental qualified NDT engineers to clients experiencing peaks in demand.
Demand for NDT has grown, driven by increasing regulation and standardisation, extension of asset lifespans, shortage in NDT expertise and the need to protect reputation from product failure and recall. Holding a number of industry accreditations and approvals essential for operation, NSL is a regional market leader in providing NDT services in the aerospace sector and a prominent operator in the power sector for the provision of on-site outsourced NDT expertise. Their NDT laboratory in the UK is widely recognised in Europe as a high quality facility.
With headquarters in Derby, UK, NSL enhances Intertek's existing quality and integrity management services for owners and operators in the aerospace, power, oil, gas and petrochemical sectors and will form part of Intertek's Industry & Assurance division. NSL provides an opportunity to build on Intertek's existing analytical and asset integrity management capabilities through the provision of high quality NDT services and direct access to a database of over 700 qualified NDT technicians.
Stefan Butz, Group Executive Vice President of Intertek's Industry & Assurance division said: "I am pleased to welcome NSL to our growing portfolio of industrial inspection and asset integrity management services. This complementary addition demonstrates Intertek's commitment to offer a complete NDT technical services proposition to our oil, gas, petrochemical and power customers. In addition, by combining Intertek's global presence and existing analytical capabilities with NSL's strong reputation and market leading position within the European aerospace we can extend a full service solution to our aerospace customers."
Graham Tomlinson, Managing Director of NDT Services Limited said: "I am very proud to have attracted the attention of such a prestigious and high profile organisation as Intertek. By joining Intertek's Industry & Assurance division NSL will have the opportunity to develop further into industries in which our highly qualified personnel have considerable expertise. The two businesses complement each other perfectly and we are looking forward to offering NDT services to Intertek's customer base. I'm sure NSL will go from strength-to-strength in both UK and European markets as part of the Intertek group."
About Intertek
Intertek is a leading provider of quality and safety solutions serving a wide range of industries around the world. From auditing and inspection, to testing, quality assurance and certification, Intertek people are dedicated to adding value to customers' products and processes, supporting their success in the global marketplace. With a network of more than 1,000 laboratories and offices and over 33,000 people in more than 100 countries, Intertek helps its clients to meet end users' expectations across increasingly diverse quality, health, environmental, safety and social accountability aspects in virtually any market around the world. Visit www.intertek.com .
About NDT Services Limited (NSL)
For further details on NSL's services and capabilities please visit www.ndtservices.co.uk .
Contact:
Sales:
NSL
Graham Tomlinson, +44 (0) 1332-275-700
graham.tomlinson@intertek.com
or
Marketing:
Intertek
Sav
Narwal, +44 (0) 20-7396-3400
sav.narwal@intertek.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom